Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-18 in Moderate to Severe Atopic Dermatitis
NCT06487000Phase 2Not yet recruiting
- Sponsor
- Enzychem Lifesciences
- Start
- May 2027
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mosedipimod in atopic dermatitis (AD), sponsored by Enzychem Lifesciences. Planned start May 2027; status: not yet recruiting.
02
Drugs
mosedipimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06487000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487000.